Sort
21,453 grants matching “tuberculosis”
Development Of New Chemotherapeutics For Tuberculosis
$6,811,260Clifton Barry · Niaid Extramural Activities · Z01 · FY2007 · AI
STRUCTURAL ORGANIZATION AND PROTEOMICS OF TB
$6,801,540University Of Calif-Los Alamos Nat Lab · P50 · FY2002 · GM
Infectious Disease Genomics: Pathogen Evolution, Emergence, and Host Interaction
$6,794,965Bruce W. Birren · Broad Institute, Inc. · U19 · FY2015 · AI
Clinical Research Products Management Center (CRPMC)
$6,780,675Putta Neeraja · Fisher Bioservices, Inc. · N01 · FY2016 · AI
Tri-Institutional TB Research Unit: Persistence and Latency
$6,756,890Carl F Nathan · Weill Medical Coll Of Cornell Univ · U19 · FY2019 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY
$6,747,982Susan Penfield · Texas State Department Of Health Srvs · U52 · FY2007 · PS
TUBERCULOSIS ELIMINATION AND LABORATORY
$6,706,616Susan Penfield · Texas State Dept Of Health Services · U52 · FY2006 · PS
Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
$6,697,676Herbert W Virgin · Washington University · U19 · FY2016 · AI
Tri-Institutional TB Research Unit: Persistence and Latency
$6,663,767Carl F Nathan · Weill Medical Coll Of Cornell Univ · U19 · FY2018 · AI
Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
$6,644,235Herbert W Virgin · Washington University · U19 · FY2017 · AI
Laboratory Center, AIDS Clinical Trials Group (ACTG); LC 2 / 3
$6,641,277Robert W. Coombs · Brigham And Women'S Hospital · UM1 · FY2016 · AI
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents
$6,639,071David S Perlin · Hackensack University Medical Center · U19 · FY2021 · AI
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents
$6,638,250David S Perlin · Hackensack University Medical Center · U19 · FY2022 · AI
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents
$6,638,108David S Perlin · Hackensack University Medical Center · U19 · FY2020 · AI
Laboratory Center, AIDS Clinical Trials Group (ACTG); LC 2 / 3
$6,624,131Robert W. Coombs · Brigham And Women'S Hospital · UM1 · FY2017 · AI
Southwest National Primate Research Center
$6,613,322John C. Kerr · Texas Biomedical Research Institute · P51 · FY2007 · RR
Clinical Research Products Management Center (CRPMC)
$6,591,581Beth Trainor-Mobley · Fisher Bioservices, Inc. · N01 · FY2015 · AI
Laboratory Center, AIDS Clinical Trials Group (ACTG); LC 2 / 3
$6,586,951Grace M. Aldrovandi · Brigham And Women'S Hospital · UM1 · FY2018 · AI
Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
$6,534,559Paul M Allen · Washington University · U19 · FY2018 · AI
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents
$6,521,325David S Perlin · Hackensack University Medical Center · U19 · FY2023 · AI
NIAID Regional Prospective Observational Research in Tuberculosis (RePORT) and Hepatitis Diagnostics
$6,500,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2023 · AI
HIV Vaccine Trials Network Laboratory Center
$6,451,056Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2025 · AI
Tri-Institutional TB Research Unit: Persistence and Latency
$6,446,187Carl F Nathan · Weill Medical Coll Of Cornell Univ · U19 · FY2020 · AI
Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents
$6,435,264Herbert W Virgin · Washington University · U19 · FY2015 · AI
Infectious Disease Genomics: Pathogen Evolution, Emergence, and Host Interaction
$6,408,353Bruce W. Birren · Broad Institute, Inc. · U19 · FY2016 · AI